# Filing Detail

Form DEF 14A - Other definitive proxy statements:
SEC Accession No. 0001640334-24-000357
Filing Date
2024-03-06
Accepted
2024-03-06 06:00:40
Documents
6
Period of Report
2024-02-27

Document Format Files

Seq | Description | Document | Type | Size
--- | --- | --- | --- | ---
1 | DEF 14A | lxrp_def14a.htm | DEF 14A | 446419
2 |  | lxrp_def14aimg1.jpg | GRAPHIC | 10328
3 |  | lxrp_def14aimg2.jpg | GRAPHIC | 177419
4 |  | lxrp_def14aimg3.jpg | GRAPHIC | 128354
5 |  | lxrp_def14aimg4.jpg | GRAPHIC | 175484
6 |  | lxrp_def14aimg5.jpg | GRAPHIC | 186184
| Complete submission text file | 0001640334-24-000357.txt |  | 1381560

Mailing Address 100 - 740 MCCURDY ROAD KELOWNA A1 V1X 2P7
Business Address 100 - 740 MCCURDY ROAD KELOWNA A1 V1X 2P7 250-765-6424
Lexaria Bioscience Corp. (Filer) CIK: 0001348362 (see all company filings)

EIN.: 202000871 | State of Incorp.: NV | Fiscal Year End: 0831
Type: DEF 14A | Act: 34 | File No.: 001-39874 | Film No.: 24724278
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)